These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

381 related items for PubMed ID: 26967222

  • 21. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.
    Doody RS, Ferris SH, Salloway S, Sun Y, Goldman R, Watkins WE, Xu Y, Murthy AK.
    Neurology; 2009 May 05; 72(18):1555-61. PubMed ID: 19176895
    [Abstract] [Full Text] [Related]

  • 22. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.
    Winblad B, Kilander L, Eriksson S, Minthon L, Båtsman S, Wetterholm AL, Jansson-Blixt C, Haglund A, Severe Alzheimer's Disease Study Group.
    Lancet; 2006 Apr 01; 367(9516):1057-1065. PubMed ID: 16581404
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease--pilot study.
    Prasher VP, Huxley A, Haque MS, Down syndrome Ageing Study Group.
    Int J Geriatr Psychiatry; 2002 Mar 01; 17(3):270-8. PubMed ID: 11921156
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of donepezil in patients with dementia with Lewy bodies: results from a 12-week multicentre, randomised, double-blind, and placebo-controlled phase IV study.
    Mori E, Ikeda M, Iseki E, Katayama S, Nagahama Y, Ohdake M, Takase T.
    Psychogeriatrics; 2024 May 01; 24(3):542-554. PubMed ID: 38439118
    [Abstract] [Full Text] [Related]

  • 31. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.
    Gold M, Alderton C, Zvartau-Hind M, Egginton S, Saunders AM, Irizarry M, Craft S, Landreth G, Linnamägi U, Sawchak S.
    Dement Geriatr Cogn Disord; 2010 May 01; 30(2):131-46. PubMed ID: 20733306
    [Abstract] [Full Text] [Related]

  • 32. Donepezil 23 mg in Asian patients with moderate-to-severe Alzheimer's disease.
    Han SH, Lee JH, Kim SY, Park KW, Chen C, Tripathi M, Dash A, Kubota N.
    Acta Neurol Scand; 2017 Feb 01; 135(2):252-256. PubMed ID: 26923256
    [Abstract] [Full Text] [Related]

  • 33. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease.
    Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD, Donepezil Study Group.
    Arch Neurol; 2001 Mar 01; 58(3):427-33. PubMed ID: 11255446
    [Abstract] [Full Text] [Related]

  • 34. A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's disease.
    Deardorff WJ, Grossberg GT.
    Drug Des Devel Ther; 2016 Mar 01; 10():3267-3279. PubMed ID: 27757016
    [Abstract] [Full Text] [Related]

  • 35. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group.
    Rogers SL, Friedhoff LT.
    Dementia; 1996 Mar 01; 7(6):293-303. PubMed ID: 8915035
    [Abstract] [Full Text] [Related]

  • 36. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial.
    Mori E, Ikeda M, Kosaka K, Donepezil-DLB Study Investigators.
    Ann Neurol; 2012 Jul 01; 72(1):41-52. PubMed ID: 22829268
    [Abstract] [Full Text] [Related]

  • 37. Donepezil in Alzheimer's disease: eighteen month results from Southampton Memory Clinic.
    Matthews HP, Korbey J, Wilkinson DG, Rowden J.
    Int J Geriatr Psychiatry; 2000 Aug 01; 15(8):713-20. PubMed ID: 10960883
    [Abstract] [Full Text] [Related]

  • 38. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials.
    Whitehead A, Perdomo C, Pratt RD, Birks J, Wilcock GK, Evans JG.
    Int J Geriatr Psychiatry; 2004 Jul 01; 19(7):624-33. PubMed ID: 15254918
    [Abstract] [Full Text] [Related]

  • 39. A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer's disease.
    Akhondzadeh S, Shafiee Sabet M, Harirchian MH, Togha M, Cheraghmakani H, Razeghi S, Hejazi SS, Yousefi MH, Alimardani R, Jamshidi A, Rezazadeh SA, Yousefi A, Zare F, Moradi A, Vossoughi A.
    Psychopharmacology (Berl); 2010 Jan 01; 207(4):637-43. PubMed ID: 19838862
    [Abstract] [Full Text] [Related]

  • 40. 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy.
    Winblad B, Wimo A, Engedal K, Soininen H, Verhey F, Waldemar G, Wetterholm AL, Haglund A, Zhang R, Schindler R.
    Dement Geriatr Cogn Disord; 2006 Jan 01; 21(5-6):353-63. PubMed ID: 16508298
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.